StockDriftsStockDriftsSamsung BioLogics (207940) has 7 disclosed insider purchases and 8 disclosed disposals on record, filed by 11 distinct insiders. Together those filings cover ₩4.2B ($2.9M) in reported transaction value. The earliest filing StockDrifts holds for Samsung BioLogics is dated 2024-04-03; the most recent is 2026-05-13. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is +0.88%, measured from each filing date to the latest available close.
| Date | Type | Source | Insider | Position | Shares | Price at filing | Return | Value |
|---|---|---|---|---|---|---|---|---|
| 2026-07-31 | SELL | Market Sell | 조성환 Seonghwan Cho | Managing Director | -50 | ₩1,485,000 | -4.8% | ₩74M ($51K) |
| 2026-05-13 | BUY | 기타 | 조성환 Seonghwan Cho | Managing Director | 50 | ₩1,410,000 | +0.3% | ₩71M ($49K) |
| 2025-12-29 | SELL | Market Sell | 김동중 Kim Dong-joong | vice president | -210 | ₩1,706,000 | -0.6% | ₩358M ($249K) |
| 2025-12-09 | BUY | Market Buy | 노균 Downy mildew | vice president | 60 | ₩1,660,000 | +3.4% | ₩100M ($69K) |
| 2025-11-28 | SELL | 증여 | 김동중 Kim Dong-joong | vice president | -400 | ₩1,607,000 | -6.8% | ₩643M ($446K) |
| 2025-11-26 | BUY | Market Buy | 진용환 Yonghwan Jin | Managing Director | 27 | ₩1,651,000 | +4.0% | ₩45M ($31K) |
| 2025-11-25 | BUY | 신규선임 | 안소연 Soyeon Ahn | Managing Director | 387 | ₩1,627,000 | +5.5% | ₩630M ($437K) |
| 2025-11-03 | SELL | 회사분할 | 삼성물산 Samsung C&T | - | -10.7M | ₩1,797,000 | +4.5% | ₩19.3T ($13.4B) |
| 2025-11-03 | SELL | 회사분할 | 삼성전자 Samsung Electronics | - | -7.8M | ₩1,797,000 | +4.5% | ₩14.0T ($9.7B) |
| 2025-11-01 | SELL | 회사분할 | 진용환 Yonghwan Jin | Managing Director | -29 | ₩1,797,000 | +4.5% | ₩52M ($36K) |
| 2025-11-01 | SELL | 회사분할 | 윤여완 Yoon Yeo-wan | Managing Director | -19 | ₩1,797,000 | +4.5% | ₩34M ($24K) |
| 2025-11-01 | SELL | 회사분할 | 제임스최 James Choi | vice president | -352 | ₩1,797,000 | +4.5% | ₩633M ($439K) |
| 2025-11-01 | SELL | 회사분할 | 김희정 Heejeong Kim | Managing Director | -1 | ₩1,797,000 | +4.5% | ₩2M ($1K) |
| 2025-11-01 | SELL | 회사분할 | 조영진 Youngjin Cho | Managing Director | -209 | ₩1,797,000 | +4.5% | ₩376M ($261K) |
| 2025-11-01 | SELL | 회사분할 | 윤종규 Jong-gyu Yoon | Managing Director | -12 | ₩1,797,000 | +4.5% | ₩22M ($15K) |
| 2025-11-01 | SELL | 회사분할 | 김기중 Kim Ki-joong | Managing Director | -30 | ₩1,797,000 | +4.5% | ₩54M ($37K) |
| 2025-11-01 | SELL | 회사분할 | 김동중 Kim Dong-joong | vice president | -1.6K | ₩1,797,000 | +4.5% | ₩2.9B ($2.0M) |
| 2025-11-01 | SELL | 회사분할 | 서상원 Seo Sang-won | Managing Director | -264 | ₩1,797,000 | +4.5% | ₩474M ($329K) |
| 2025-11-01 | SELL | 회사분할 | 홍연진 Yeonjin Hong | Managing Director | -11 | ₩1,797,000 | +4.5% | ₩20M ($14K) |
| 2025-11-01 | SELL | 회사분할 | 황인찬 Inchan Hwang | Managing Director | -16 | ₩1,797,000 | +4.5% | ₩29M ($20K) |
| 2025-11-01 | SELL | 회사분할 | 유승호 Seungho Yoo | vice president | -70 | ₩1,797,000 | +4.5% | ₩126M ($87K) |
| 2025-11-01 | SELL | 회사분할 | John Chongbo Rim | CEO | -140 | ₩1,797,000 | +4.5% | ₩252M ($175K) |
| 2025-11-01 | SELL | 회사분할 | 이규호 Gyuho Lee | vice president | -35 | ₩1,797,000 | +4.5% | ₩63M ($44K) |
| 2025-11-01 | SELL | 회사분할 | 이재선 Jaeseon Lee | Managing Director | -95 | ₩1,797,000 | +4.5% | ₩171M ($119K) |
| 2025-09-02 | BUY | Market Buy | 이규호 Gyuho Lee | vice president | 100 | ₩1,467,329 | +17.0% | ₩147M ($102K) |
| 2025-08-29 | BUY | Market Buy | John Chongbo Rim | CEO | 200 | ₩1,473,216 | +16.6% | ₩295M ($205K) |
| 2025-08-29 | BUY | Market Buy | 유승호 Seungho Yoo | vice president | 200 | ₩1,473,216 | +16.6% | ₩295M ($205K) |
| 2025-08-28 | BUY | Market Buy | John Chongbo Rim | CEO | 200 | ₩1,489,405 | +15.3% | ₩298M ($207K) |
| 2025-07-14 | SELL | Market Sell | 박용 Park Yong | Managing Director | -465 | ₩1,533,557 | -12.0% | ₩713M ($495K) |
| 2025-07-04 | BUY | 기타 | 박용 Park Yong | Managing Director | 465 | ₩1,527,670 | +12.4% | ₩710M ($493K) |
| 2025-06-18 | SELL | Market Sell | 조성일 Jo Seong-il | Managing Director | -195 | ₩1,477,631 | -16.2% | ₩288M ($200K) |
| 2025-02-11 | SELL | Market Sell | 심병화 Shim Byeong-hwa | Managing Director | -200 | ₩1,727,828 | +0.6% | ₩346M ($240K) |
| 2024-12-26 | BUY | Market Buy | 윤여완 Yoon Yeo-wan | Managing Director | 40 | ₩1,379,024 | +24.5% | ₩55M ($38K) |
| 2024-12-26 | BUY | 기타 | 심병화 Shim Byeong-hwa | Managing Director | 494 | ₩1,379,024 | +24.5% | ₩681M ($473K) |
| 2024-12-26 | SELL | Market Sell | 심병화 Shim Byeong-hwa | Managing Director | -200 | ₩1,379,024 | -24.5% | ₩276M ($192K) |
| 2024-12-06 | BUY | 신규선임 | 윤여완 Yoon Yeo-wan | Managing Director | 14 | ₩1,415,818 | +21.3% | ₩20M ($14K) |
| 2024-12-04 | BUY | 기타 | 조성일 Jo Seong-il | Managing Director | 195 | ₩1,414,346 | +21.4% | ₩276M ($192K) |
| 2024-11-29 | BUY | 신규선임 | 황인찬 Inchan Hwang | Managing Director | 44 | ₩1,434,950 | +19.7% | ₩63M ($44K) |
| 2024-10-30 | SELL | Market Sell | 박세강 Park Se-gang | Managing Director | -156 | ₩1,517,368 | -13.2% | ₩237M ($164K) |
| 2024-09-26 | SELL | Market Sell | 진용환 Yonghwan Jin | Managing Director | -200 | ₩1,548,275 | -10.9% | ₩310M ($215K) |
| 2024-09-23 | SELL | Market Sell | 진용환 Yonghwan Jin | Managing Director | -292 | ₩1,599,786 | -7.3% | ₩467M ($324K) |
| 2024-07-01 | BUY | 신규선임 | 이재선 Jaeseon Lee | Managing Director | 270 | ₩1,117,054 | +53.7% | ₩302M ($209K) |
| 2024-05-22 | BUY | 기타 | 진용환 Yonghwan Jin | Managing Director | 353 | ₩1,143,545 | +50.1% | ₩404M ($280K) |
| 2024-04-03 | BUY | 기타 | 조영진 Youngjin Cho | Managing Director | 395 | ₩1,195,056 | +43.7% | ₩472M ($328K) |
Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Samsung BioLogics. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.